ABEO
$4.76
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Intraday
Recent News
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ...
Abeona Therapeutics Inc (ABEO) reports growing patient demand and significant financial gains, despite facing operational hurdles in launching its groundbreaking gene therapy.
Abeona Therapeutics Q4 Earnings Call Highlights
Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), while outlining early commercial tractio
Abeona (ABEO) Q4 2025 Earnings Call Transcript
Treating our first commercial patient this past December was a significant milestone for Abeona Therapeutics Inc., but 2026 is where the launch execution ramps up. All patient treatments and biopsies performed to date have come from the first two of our four qualified treatment centers, Lurie Children's Hospital in Chicago and Lucile Packard Children's Hospital at Stanford. This momentum provides Abeona Therapeutics Inc. an opportunity to demonstrate that the operational machine behind ZevaSkin works at scale from initial biopsy through final delivery.
Abeona Therapeutics: Q4 Earnings Snapshot
CLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Tuesday reported a loss of $20.5 million in its fourth quarter. On a per-share basis, the Cleveland-based company said it had a loss of 34 cents.
Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026
Abeona Therapeutics (NASDAQ:ABEO) executives said the commercial launch of ZEVASKYN is gaining momentum after an early manufacturing-related delay, outlining progress on treatment center activation, patient onboarding, and capacity expansion during remarks at the Leerink Partners Global Healthcare C